Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Anti-Aging

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

Articles

Researchers noted that further examination and monitoring for headache disorders in patients with atopic dermatitis may be warranted.

Atopic Dermatitis Identified as Possible Risk Factor for Headache Disorders, Migraine

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Researchers compared a variable-sequenced, large-spot 532 nm KTP laser to the 595 nm pulsed-dye laser.

Variable-Sequenced Large-Spot KTP and PDL Demonstrate Comparable Efficacy in Rosacea

Data stems from week 28 results of the German G-EPOSS study evaluating the effectiveness of guselkumab in skin health, quality of life, sexuality, and stigmatization.

Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment and Stigmatization

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.

Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

Terry Allman, C.P.C., Q.P.A., Q.K.A., C.R.P.C.

Articles